| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Lu Hongbo serves as a Director at ZBIO and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 16 buys and 1 sell. Those positions are worth an estimated $14.5M at current prices.
Historically, Lu Hongbo's trades have earned a middling insider score of 59/100 across 11 rated trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of +2.3%.
The biggest single holding is ZBIO (~$8.5M) as Director. Net of sales, the recent Form 4 record there shows accumulation of 485,559 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 16, 2022 | TERN Terns Pharmaceuticals, Inc. | Director | Buy | 2,624,239 | $2.66 | $6,980,244.40 | +734.4% | -7.2% | +14.3% |